🕵️ Kalvista Pharmaceuticals, Inc. ($KALV)
SEC insider & ownership activity, last 12 months · CIK 1348911 · every row links its SEC filing
Insider sell value was withheld pending verification over the last 12 months. One red-flag 8-K in the window: Delisting notice (3.01), Jun 11, 2026.
Insider flow
0 buyers, $0 (0 lots) · 6 sellers, value withheld pending verification (42 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Benjamin L. Palleiko | 0 | – | 12 | value withheld pending verification | May 22, 2026 |
| Paul K. Audhya | 0 | – | 8 | value withheld pending verification | May 26, 2026 |
| Yea Christopher | 0 | – | 8 | value withheld pending verification | May 27, 2026 |
| Sweeny Nicole | 0 | – | 5 | value withheld pending verification | May 26, 2026 |
| Piekos Brian | 0 | – | 4 | value withheld pending verification | May 22, 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 0 | – | 5 | value withheld pending verification | Mar 26, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Bong Y. Koh | 10.1% | 13G | Feb 3, 2025 | filing ↗ | |
| Capital World Investors | 6.4% | 13G | May 13, 2025 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Christopher M. Yea | $905K | May 27, 2026 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Material agreement (1.01) | Jun 11, 2026 | filing ↗ |
| Agreement terminated (1.02) | Jun 11, 2026 | filing ↗ |
| Acquisition or disposition (2.01) | Jun 11, 2026 | filing ↗ |
| New financial obligation (2.03) | Jun 11, 2026 | filing ↗ |
| Delisting notice (3.01) | Jun 11, 2026 | filing ↗ |
| Material Modifications to Rights of Security Holders (3.03) | Jun 11, 2026 | filing ↗ |
| Change of control (5.01) | Jun 11, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 11, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Jun 11, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 11, 2026 | filing ↗ |
| Material agreement (1.01) | Apr 29, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 29, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 29, 2026 | filing ↗ |
| Earnings (2.02) | Mar 25, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 25, 2026 | filing ↗ |
| Earnings (2.02) | Jan 8, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 8, 2026 | filing ↗ |
| Earnings (2.02) | Nov 10, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 10, 2025 | filing ↗ |
| Officer/director changes (5.02) | Oct 6, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Oct 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Oct 6, 2025 | filing ↗ |
| Officer/director changes (5.02) | Oct 1, 2025 | filing ↗ |
| Shareholder vote (5.07) | Oct 1, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Oct 1, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Oct 1, 2025 | filing ↗ |
| Material agreement (1.01) | Sep 24, 2025 | filing ↗ |
| New financial obligation (2.03) | Sep 24, 2025 | filing ↗ |